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 Background . Crotalidae Polyvalent Immune Fab (Ovine) has been the only antivenom commercially available in the US since 2007 
for treatment of Crotalinae envenomation. Late coagulopathy can occur or recur after clearance of Fab antivenom, often after hospital 
discharge, lasting in some cases more than 2 weeks. There have been serious, even fatal, bleeding complications associated with recurrence 
phenomena. Frequent follow-up is required, and additional intervention or hospitalization is often necessary. F(ab ’ ) 2 immunoglobulin 
derivatives have longer plasma half life than do Fab. We hypothesized that F(ab ’ ) 2 antivenom would be superior to Fab in the prevention 
of late coagulopathy following treatment of patients with Crotalinae envenomation.  Methods . We conducted a prospective, double-blind, 
randomized clinical trial, comparing late coagulopathy in snakebitten patients treated with F(ab ’ ) 2 with maintenance doses [F(ab ’ ) 2 /
F(ab ’ ) 2 ], or F(ab ’ ) 2 with placebo maintenance doses [F(ab ’ ) 2 /placebo], versus Fab with maintenance doses [Fab/Fab]. The primary 
effi cacy endpoint was coagulopathy (platelet count    150 K/mm 3 , fi brinogen level    150 mg/dL) between end of maintenance dosing and 
day 8.  Results . 121 patients were randomized at 18 clinical sites and received at least one dose of study drug. 114 completed the study. 
Of these, 11/37 (29.7%) in the Fab/Fab cohort experienced late coagulopathy versus 4/39 (10.3%,  p    0.05) in the F(ab ’ ) 2 /F(ab ’ ) 2 cohort 
and 2/38 (5.3%,  p    0.05) in the F(ab ’ ) 2 /placebo cohort. The lowest heterologous protein exposure was with F(ab ’ ) 2 /placebo. No serious 
adverse events were related to study drug. In each study arm, one patient experienced an acute serum reaction and one experienced serum 
sickness.  Conclusions . In this study, management of coagulopathic Crotalinae envenomation with longer-half-life F(ab ’ ) 2 antivenom, 
with or without maintenance dosing, reduced the risk of subacute coagulopathy and bleeding following treatment of envenomation. 
Keywords  Snakes; Antivenins; Toxinology 
 Introduction 
 Background 
 Snakebites are an important threat to public health. World-
wide, more than 5 million bites result in as many as 94,000 
deaths annually. Almost one-fourth of global snakebite inci-
dence occurs in America, although mortality is relatively low 
compared with that in Africa and Asia. 1 In the US, thousands 
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of bites are reported each year, but fewer than half a dozen 
are fatal. 2,3 Snakebite mortality has decreased through the 
years and in certain regions of the world, in part because 
of the development of safe and effective antivenoms. 4,5 
Antivenoms bind and neutralize venom toxins, and facili-
tate redistribution away from target tissues and elimination 
from the body. 6,7 Antivenom production involves collecting 
venom from a medically signifi cant organism and inoculat-
ing a suitable domestic animal. 8 Sublethal amounts generate 
immunity, and antibodies are obtained from the plasma of 
the immunized animal. 9 Adverse drug reactions to early, 
unrefi ned antiserums were frequent, often severe and some-
times fatal. 5,10,11 Physicians were, therefore, hesitant to use 
antivenom, and fear of dangerous side effects led to delays 
in administration and to insuffi cient dosing. Most modern 
antivenoms undergo further modifi cation, 9,12,13 including 
plasma fractionation, protein precipitation, ion-exchange or 
affi nity chromatography, ultra- and nanofi ltration, addition 
of preservative, lyophilization, and the regulation via Good 
Manufacturing Practices for quality control and minimiza-
tion of microbial contamination. Further, many manufactur-
ers enzymatically reduce the crude Immunoglobulin G (IgG) 
molecule to yield antigen-binding fragments. The Y-shaped 
IgG is cleaved with pepsin to yield a V-shaped F(ab ’ ) 2 or 
with papain to generate two Fab fragments. The Fc por-
tion (the stem of the Y), suspected for causing most of the 
adverse reactions, is removed along with other non-neutral-
izing components. Immune reactions are now markedly less 
problematic than those with earlier and less ameliorated 
preparations. 4,5 
 Importance 
 However, another kind of clinical problem emerged as 
Fab antivenom gained widespread use in the US, 7 where it 
has been the only commercially available antidote for pit 
viper (Crotalinae) envenomation since 2007. 14 Rattlesnake 
( Crotalus and Sistrurus spp. ) envenomation commonly 
causes thrombocytopenia and hypofi brinogenemia. 15 – 17 
These venom-induced coagulopathies usually improve, but an 
estimated one-third to more than one-half of them recur in the 
days to weeks following treatment with Fab antivenom. 18,19 
Recurrent coagulopathy is almost always as severe as the 
presenting coagulopathy and sometimes worse. 20 In addi-
tion, new-onset late coagulopathies develop in many 
instances despite a full course of Fab antivenom treatment. 
When exactly and if coagulation abnormalities will develop 
and nadir are diffi cult to predict. 21,22 Furthermore, coagul-
opathies sometimes persist, even with repeated doses of Fab 
antivenoms, and transfusions are ineffective. 9,23 Studies in 
Asia and Africa conclude that more often repeated doses of 
Fab antivenoms are not required with antigen-binding frag-
ment antivenoms, but that F(ab ’ ) 2 is more effective than Fab 
at restoring blood coagulability. 24,25 Frequent monitoring 
and follow-up are necessary with Fab antivenoms, along 
with additional intervention, hospitalization and cost. 22 Seri-
ous bleeding complications and deaths have resulted from 
late coagulopathies after treatment of viper (e.g.,  Crotalus 
adamanteus  *  , C. atrox, C. ruber  *  , C. oreganus oreganus , 
C. horridus , and  Bothrops alternatus  *  ; Viperidae) enveno-
mation with a Fab antivenom. 23,26 – 30 [ * - deaths] 
 Goals of this investigation 
 Recurrence of coagulopathy appear, at least in part, to be 
caused by a pharmacokinetic mismatch between venom and 
antivenom, probably because a depot of venom remains at 
the bite site, distributing into the surrounding tissues and 
circulation according to the properties and kinetics of its var-
ious toxins. 9 IgG, F(ab ’ ) 2 , and Fab differ in molecular mass, 
volume of distribution, and elimination half-life. 9 A Phase 2 
clinical trial explored the relationship of venom antigenemia 
( “ venonemia ” ) with recurrent coagulopathy, showing a clear 
difference between the patterns with F(ab ’ ) 2 versus Fab anti-
venom during the 2 weeks following treatment of enveno-
mation. 18 No recurrence was observed in patients treated 
with F(ab ’ ) 2 in preliminary Phase 2 study, but larger studies 
were necessary for confi rmation or negation of this fi nding. 
We hypothesized that F(ab ’ ) 2 antivenom would be superior 
to Fab in the prevention of late coagulopathy following 
treatment of envenomation. To test this hypothesis, we 
conducted a prospective, multicenter, blinded, randomized, 
controlled Phase 3 clinical trial comparing F(ab ’ ) 2 to Fab for 
the treatment of patients with Crotalinae envenomation. 
 Methods 
 Study design 
 In this prospective, blinded, randomized, controlled clinical 
trial, prevention of late coagulopathy using F(ab ’ ) 2 versus 
Fab antivenom was compared in treatment of Crotalinae 
envenomation at 18 clinical sites in the US. The Institutional 
Review Board at each site approved the study protocol. 
The study was registered at ClinicalTrials.gov, number 
NCT00636116. 
 Materials 
 The Fab antivenom was Crotalidae polyvalent immune 
Fab (ovine) (CroFab  ®  ,  “ Fab ” ), a commercial product. Immu-
nizing venoms used to produce it are from 
 C. adamanteus ,  C. atrox ,  C. scutulatus , and  Agkistrodon 
piscivorus . This preparation is purifi ed via sodium sulfate 
precipitation and affi nity chromatography. Protein content of 
each vial is  “ up to 1 g, ” according to the manufacturer. 12 
 The F(ab ’ ) 2 antivenom was Crotalidae equine immune 
F(ab ’ ) 2 [Anavip 
 ®  ,  “ F(ab ’ ) 2 ” ], an investigational new drug. 
Immunizing venoms for this product are from  B. asper and 
 C. simus . This preparation is purifi ed via ammonium sulfate 
precipitation and fi ltration. F(ab ’ ) 2 contains approximately 
120 mg of protein per vial. 13 A relative potency of one vial 
of Fab to two vials of F(ab ’ ) 2 was assigned based on a 
Phase 2 clinical trial and mouse ED 50 comparisons. 
18,31 
Study drugs and monitoring were provided by sponsors 
Instituto Bioclon, SA de CV, and Rare Disease Therapeu-
tics, Inc. 
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 “ Study drug ” was whichever antivenom and/or placebo 
combination the subject was randomized to receive. 
 Selection of participants 
 Eligible patients were males and females aged 2 – 80 years 
presenting for emergency treatment of a Crotalinae bite and 
able to provide informed consent. Signs of envenomation 
(as judged by clinician investigators) were swelling, tender-
ness, redness, ecchymosis, or blebs emanating from the bite 
site; decreased platelets or fi brinogen; and hypotension, 
bleeding beyond the puncture site, refractory vomiting or 
diarrhea, angioedema, or neurotoxicity. Exclusion criteria 
included pregnancy; breast-feeding; current treatment with 
antivenom or treatment with antivenom within the last 
month; participation in a clinical trial within the previous 
month; allergy to horse serum, sheep serum, or papaya; no 
clinical indications of snakebite requiring antivenom for 
treatment (i.e., no local tissue injury other than tooth marks 
and no lab abnormalities or systemic abnormalities consis-
tent with snake venom toxicity); and underlying medical 
conditions or medications that signifi cantly alter platelet 
count or fi brinogen. The study took place from May 2008 
through September 2011, and patients were followed for 
22 days after enrollment. 
 Interventions 
 Randomization was done using Statistical Analysis Soft-
ware (Cary, NC). Three treatment arms [F(ab ’ ) 2 with F(ab ’ ) 2 
maintenance therapy, F(ab ’ ) 2 with placebo maintenance 
therapy, and Fab with Fab maintenance therapy] were estab-
lished, in a 1:1:1 ratio with a block size of 6. After informed 
consent was granted, a study pharmacist contacted an Inter-
active Voice Response System (Covance, Inc, Princeton NJ) 
to learn the group assignment. Study drug was reconstituted 
and diluted to 250 mL with normal saline (NS). Placebo con-
sisted of 250 mL of NS only. To ensure blinding of all other 
participants, study drug was provided to clinicians with no 
reference to group assignment. Study subjects, all investiga-
tors and care providers, the IND sponsor, and study monitors 
remained blinded until completion of the study. 
 Study drug was infused intravenously over 1 hour. Ini-
tial dose(s) consisted of 10 vials of F(ab ’ ) 2 or 5 vials of Fab 
administered every 2 hours until  “ Initial Control ” of the 
envenomation was achieved, meaning that (1) the leading 
edge of local injury was not progressing more than 1 inch 
per hour, and (2) platelet count, serum fi brinogen level, pro-
thrombin time (PT), and partial thromboplastin time (PTT) 
were either normal or returning toward normal. After initial 
control, maintenance dosing of 4 vials of F(ab ’ ) 2 [for the 
F(ab ’ ) 2 /F(ab ’ ) 2 group] or 250 mL of NS [for the F(ab ’ ) 2 /
placebo group] or 2 vials of Fab (for the Fab/Fab group) was 
administered every 6 hours for 3 doses. At any time during 
the study, patients with ongoing signs of envenomation could 
receive an additional 4 vials of F(ab ’ ) 2 or 2 vials of Fab, in 
accordance with group assignment, at physician discretion, 
maintaining the blind. 
 Measurements 
 Patients had the following assessments and measurements 
recorded at baseline: history, medications, vital signs, 
physical examination, and a urine or blood pregnancy test; 
blood was drawn for complete blood count (CBC) PT/PTT, 
fi brinogen, venom, and antivenom levels; the subfamily, 
genus, and species of the snake were identifi ed if possible; 
the physician or study nurse drew a line on the patient ’ s 
skin indicating the proximal leading edge of the lesion; 
and Snakebite Severity Score (SSS) 32 was assessed. On 
completion of the initial infusion, the physician or study 
nurse drew another line on the patient ’ s skin to compare 
with the previous line and to facilitate subsequent assess-
ments of ongoing local injury. Lesion assessment and repeat 
labs (CBC, PT/INR (International Normalized Ratio), 
fi brinogen, and venom/antivenom levels) were drawn 
2 hours after the start of the initial infusion and 2 hours 
after the start of each additional infusion until initial con-
trol was achieved. Vitals were repeated 2 hours after start 
of each maintenance dose, and lab tests were repeated 
2 hours after start of the third maintenance dose. At each 
follow-up visit on days 5, 8, and 15, patients had vitals taken, 
lab results obtained, and an assessment for any symptoms 
or signs suggestive of recurrent venom effect or adverse 
event (AE). The reason for this periodicity of follow-up was 
based on the documented range of recurrence chronology. 
During the follow-up phone call on day 22, concomitant 
medications and AEs were reviewed with the patient. 
 Outcomes 
 The  primary effi cacy endpoint was defi ned as coagulopa-
thy between the end of maintenance dosing and study day 
8 (  /   1 day). Coagulopathy was defi ned as platelet count 
less than 150,000/mm 3 , fi brinogen less than 150 mg/dL, or 
use of antivenom to treat a coagulation abnormality between 
the end of maintenance dosing and study day 5.  Second-
ary effi cacy endpoints included platelet counts, fi brinogen 
levels, and venom levels. 
 Safety monitoring included specifi c overall assessment 
for acute and delayed serum reactions, clinical evidence of 
bleeding or coagulopathy, and other individual AEs regard-
less of apparent cause. AE seriousness, frequency, intensity, 
relationship to study drug, action taken, and outcome were 
recorded and clinically judged by investigators. AEs were 
monitored for 22 days. 
 Data analysis 
 Sample size calculations were based on predicted rates of 
coagulopathy during follow-up of 35 percent for Fab and 
5 percent for F(ab ’ ) 2 . This difference in proportions would 
yield a moderate effect size. Under these assumptions, a 
sample size of 36 patients per treatment group gave greater 
than 80% power to detect a difference in coagulopathy 
rates between treatments. The total number (108) was later 
amended to 120, to allow a reasonable power for analyses 
even if up to 10% of patients withdrew from the study or were 
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eliminated because of protocol deviations. The trial ended 
when the enrollment goal was reached. The primary effi cacy 
analysis was based on the intent-to-treat (ITT) population. 
 The null hypothesis assumed no difference in coagulopa-
thy incidence between treatments, the alternative hypothesis 
is that F(ab ’ ) 2 is superior to Fab. Any fi brinogen level less 
than 60 was analyzed as 60 mg/dL, favoring the null hypoth-
esis. For the primary effi cacy endpoint, separate pairwise 
comparisons between each F(ab ’ ) 2 group versus the Fab 
group were performed using Fisher ’ s exact test. The Bonfer-
roni – Holm method was used to preserve a family-wise type 
I error rate of 0.05. 33 For all other analyses, a similar method 
was employed. Categorical outcomes were analyzed using 
Fisher ’ s exact test; continuous outcomes were analyzed 
using analysis of variance (ANOVA). Statistical analyses 
were performed using IBM SPSS Statistics for Macintosh, 
21.0, Armonk, NY, and power calculation was performed 
using PASS 2005, NCSS, LLC, Kaysville, UT. 
 Results 
 Characteristics of study subjects 
 A total of 123 patients were randomized, 41 in each group, 
of which 121 received antivenom and 114 completed the 
study (Fig. 1). There were no differences in gender, eth-
 Fig. 1 . CONSORT fl ow diagram (colour version of this fi gure can be found in the online version at www.informahealthcare.com/ctx). 
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nicity, baseline mean platelet count or fi brinogen level, 
SSS, or time to antivenom administration among groups 
(Table 1). The F(ab ’ ) 2 /F(ab ’ ) 2 group included more children 
and was younger on average than the Fab/Fab group. Eigh-
teen study sites in 8 states participated in the study: AZ, CA, 
FL, KS, LA, NC, NM, and TX. Protocol deviations related 
to study drug type or dose occurred in 6 cases. The identifi ed 
snake species included  C. oreganus helleri ,  C. scutulatus , 
 C. mitchellii ,  C. atrox ,  C. cerastes ,  C. ruber ,  C. viridis ,  C. 
molossus ,  C. horridus ,  S. miliarius barbouri ,  A. contortrix, 
and a single  A. piscivorus . Copperhead bites affected 6 in the 
F(ab ’ ) 2 /F(ab ’ ) 2 group, 7 in F(ab ’ ) 2 /placebo group, and 8 in 
the Fab/Fab group. One cottonmouth bite was identifi ed in 
the Fab/Fab group. The rest were rattlesnake or unidentifi ed 
bites ( n    102). 
 Effi cacy 
 Coagulopathy was less frequent in the F(ab ’ ) 2 /F(ab ’ ) 2 and 
the F(ab ’ ) 2 /placebo groups compared with that in the Fab/
Fab group, and there was an absolute risk reduction in both 
F(ab ’ ) 2 groups compared with that in Fab group (Table 2). The 
lowest platelet counts were lower in the Fab group compared 
with those in both the F(ab ’ ) 2 groups. The lowest fi brinogen 
levels were lower in the Fab group compared with those in 
the F(ab ’ ) 2 /placebo group. The only patients with fi brinogen 
levels less than 60 mg/dL ( n    2) and platelet counts less 
than 50,000/mm 3 ( n    2) after initial control were in the Fab 
group. Post-hoc review of venom and antivenom levels by 
Instituto Bioclon suggested that analyte degradation during 
transport and prolonged storage at -20 may have reduced 
signal intensity to such an extent that comparison of results 
across groups was invalidated. For this reason, these results 
were excluded from this analysis. 
 None of the children    10 years old ( n    18; 15.8%) 
experienced late coagulopathy. Six extra doses were given 
to F(ab ’ ) 2 /F(ab ’ ) 2 recipients, eleven to F(ab ’ ) 2 /placebo 
recipients, and eighteen to Fab/Fab recipients. Of 6 patients 
treated with F(ab ’ ) 2 who experienced late coagulopathy, all 
manifested at a single site in inland southern California; 
the species, identifi ed by the fi rst author, were  C. oreganus 
helleri ( n    2), C. mitchellii ,  C. ruber ,  C. atrox , and one 
unknown  Crotalus sp. Late coagulopathy occurred in Fab 
patients at 7 sites: in California ( n    8), Arizona ( n    5), New 
Mexico ( n    2), Florida ( n    1), and North Carolina ( n    1). 
Removal of protocol deviation cases from the ITT analysis 
did not affect signifi cance of results. 
 Adverse events and safety 
 Overall, fewer AEs were reported in the F(ab ’ ) 2 /placebo 
group than in the F(ab ’ ) 2 /F(ab ’ ) 2 or Fab/Fab (Table 3). The 
majority of events reported in all three of the study groups 
were assessed as mild. 
 Table 1 . Demographic and baseline characteristics of the patients. * 
F(ab ’ ) 2 /F(ab ’ ) 2 F(ab ’ ) 2 /Placebo Fab/Fab
Variable ( N    41) ( N    40) ( N    40)
Age  – yr
Mean 32.9  †    22.26 40.3    21.02 45.6    16.52
Median 36 43 48
Range 2 – 80 7 – 77 5 – 80
Age    10 yrs  – no. (%) 12  ‡  (29.3) 5 (12.5) 1 (2.5)
Female gender- no. (%) 11 (26.8) 10 (25.0) 12 (30.0)
Ethnicity- no. (%)
White 29 (70.7) 31 (77.5) 26 (65.0)
Hispanic 8 (19.5) 7 (17.5) 10 (25.0)
Black 3 (7.3) 1 (2.5) 2 (5.0)
Native American 1 (2.4) 1 (2.5) 2 (5.0)
Baseline platelet count  – K/mm 3 
Mean 197.1    100.7 223.6    85.7 189.5    79.3
Median 185.5 221.0 199.5
Range 15 – 400 26 – 382 35 – 348
Baseline fi brinogen level  – mg/dL
Mean 275.8    129.2 276.5    98.5 268.4    86.6
Median 256.0 293.0 267.0
Range 60 – 718 20 – 475 60 – 438
Snakebite Severity Score 31 
Mean 3.8    2.10 3.0    l.51 3.8    2.33
Median 3.0 3.0 3.0
Range 1 – 11 1 – 7 1 – 11
Bite-to-antivenom start time  – hrs
Mean 6.4    6.22 4.9    3.44 8.7    10.93
Median 4.4 3.5 4.5
Range 2.1 – 35.5 1.8 – 18.7 1.6 – 58.7
  *  Plus-minus values are means   SD. 
  †  p    0.05, One-way ANOVA, compared with Fab/Fab. 
  ‡  p    0.05, Fisher ’ s exact test, compared with Fab/Fab. 
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 Nine patients experienced Serious AEs (SAEs), all 
assessed as unrelated to study drug. One patient in the 
F(ab ’ ) 2 /F(ab ’ ) 2 group died on Day 7 from injuries related 
to a traffi c collision. One SAE in the Fab/Fab group was 
related to multicomponent coagulopathy recurrence and 
persistence, with major extension of ecchymosis on day 2, 
bleeding from an intrajugular intravenous site on day 6, 
and a 10-g drop in hemoglobin during an 11-day hospital 
course. 
 One patient in each arm of the study experienced an 
acute serum reaction; however, all three tolerated sub-
sequent doses after resolution of the AEs. One patient in 
each group experienced a pattern of symptoms suggestive 
of serum sickness during follow-up. No immune reaction 
was severe. 
 Mean antivenom dose in terms of vials was similar for 
the F(ab ’ ) 2 /placebo (16.1    7.89, range: 5 – 38) and Fab/Fab 
(14.2    5.66, range: 7 – 38) groups, but greater in the F(ab ’ ) 2 /
F(ab ’ ) 2 (27.2    7.25, range: 22 – 46) group. Maximum total 
protein exposure was 3.5 – 6 times greater in the Fab group 
than that in either of the F(ab ’ ) 2 groups. 
 Discussion 
 This study supports the hypothesis that management of 
US Crotalinae envenomation using an F(ab ’ ) 2 antivenom 
reduces subacute coagulopathies following treatment in 
comparison with that using Fab antivenom. An absolute 
risk reduction of 19.5 – 24.5 percent would suggest that 
4 – 5 patients would need to be treated with F(ab ’ ) 2 to result 
in fewer cases of late coagulopathy. Serious bleeding com-
plications after treatment with Fab occurred in our study, 
consistent with past reports. 23,26 – 30 This implies that use 
of F(ab ’ ) 2 antivenom could reduce medically signifi cant 
late bleeding after snakebite, and that the need for repeated 
blood testing after treatment could be reduced. In addition, 
our study suggests that maintenance dosing is not required 
with F(ab ’ ) 2 to prevent late coagulopathy. 
 Table 2.  Effi cacy endpoints. 
 
F(ab ’ ) 2 /F(ab ’ ) 2 
( N    39)
F(ab ’ ) 2 /placebo
( N    38)
Fab/Fab
( N    37)
Experienced late coagulopathy — No. (%) 4 (10.3)  ‡  2 (5.3)  ‡  11 (29.7)
Absolute risk reduction (95% Cl)  *  0.195 (0.014 – 0.367) 0.245 (0.073 – 0.410)  – 
Number needed to treat (patients)  *  Approximately 5 Approximately 4  – 
Mean platelet count, 1,000 s per mm   SD (range)
Day 5 265.2    81.4 (121 – 434) 259.5    61.4 (132 – 374) 227.1    70.0 (77 – 389)
Day 8 266.8    84.7 (125 – 447) 265.0    73.5 (114 – 424) 234.1    80.8 (40 – 415)
Mean fi brinogen, mg/dL   SD (range)
Day 5 369.4    75.1 (223 – 530) 394.7    97.7 (173 – 650) 364    116.5 (81 – 564)
Day 8 344.7    70.9 (208 – 477) 387.1    96.0 (195 – 693) 334.8    114.4 (105 – 589)
Lowest platelet count, 1,000 s per mm 3    SD (range)
253.4  †    80.3 (121 – 434) 247.5  †    62.6 (114 – 374) 208.9    76.9 (40 – 389)
Lowest fi brinogen, mg/dL   SD (range)
340.0    70.0 (208 – 477) 367.8  †    93.9 (173 – 650) 309.0    116.4 (   60 – 564)
  *  Compared with Fab/Fab  . 
  †  p    0.05, One-way ANOVA, compared to Fab/Fab. 
  ‡  p    0.05, Fisher ’ s exact test, compared to Fab/Fab. 
 Table 3 . Adverse events (Safety population). 
Event
F(ab ’ ) 2 /F(ab ’ ) 2 * 
( N    43)
F(ab ’ ) 2 /Placebo * 
( N    37)
Fab/Fab 
( N    41)
Number of AEs 130 72 137
Patients reporting at least 1 AE — No. (%) 35 (81.4) 24 (64.9) 33 (80.5)
Itching (pruritus) — No. (%) 20 (46.5) 14 (37.8) 20 (48.8)
Easy bruising, gingival bleeding, petechiae or melena — No. (%) 4 (9.3) 3 (8.1) 10 (24.4)
Nausea, vomiting — No. (%) 8 (18.7) 6 (16.2) 7 (17.0)
Rash  — No. (%) 5 (11.6) 5 (13.5) 5 (12.2)
Arthralgia — No. (%) 4 (9.3) 4 (10.8) 7 (17.1)
Myalgia — No. (%) 3 (7.0) 3 (8.1) 8 (19.5)
Dehydration — No. (%) 2 (4.7) 0 (0.0) 4 (9.8)
Chest pain — No. (%) 0 (0.0) 1 (2.7) 2 (4.9)
Other (fever, headache, cellulitis, diarrhea, pain, fatigue or blisters) — No. (%) 18 (41.9) 11 (29.7) 17 (41.5)
Serious adverse events — No. (%) 6 (14.6) 1 (2.7) 2 (4.9)
Immune reactions
Acute serum reaction — No. (%) 1 (2.3) 1 (2.7) 1 (2.4)
Serum sickness — No. (%) 1 (2.3) 1 (2.7) 1 (2.4)
 * No pairwise comparison with Fab/Fab was signifi cant using Fisher ’ s exact test. 
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 The specifi c F(ab ’ ) 2 and Fab antivenoms compared in this 
study differ in many ways, most obviously not only in the 
structure and mass of the molecule but also in the venom 
immunogens used, affi nity purifi cation, protein content, 
and pharmacokinetics. Each of these variables could have 
infl uenced effi cacy, and so each is considered. First, Fab is 
produced using venoms from snake species indigenous to 
the US, whereas venoms for manufacturing F(ab ’ ) 2 come 
from Latin American species. Venom composition and 
antigenicity can vary considerably with species 34 and geo-
graphic 35 origin of a snake; it is commonly assumed that 
venom immunogens derived from local species produce 
more regionally effective antivenom. 24 Our study showed 
the opposite, suggesting that this was less important than 
other factors. Second, Fab is affi nity purifi ed while F(ab ’ ) 2 
is not. Effective affi nity purifi cation should favor the per-mg 
potency and effi cacy of Fab, again in contradistinction to 
our results, which favored the lower-protein, non-affi nity-
purifi ed F(ab ’ ) 2 antivenom. Finally, Phase 2 data showed 
that clearance of Fab is associated with recurring venom 
antigenemia and an accompanying drop in platelet count 
and fi brinogen levels, in contrast with F(ab ’ ) 2 , which cleared 
more slowly and was not associated with recurrent venom 
effects. 18 This difference is consistent with our Phase 3 fi nd-
ings. Therefore, we conclude that differences in incidence 
of coagulopathy are principally related to antivenom kinet-
ics. This is consistent with fi ndings in a comparative study 
of F(ab ’ ) 2 and Fab antivenoms for  Echis ocellatus enveno-
mations in Nigeria 25 and in a comparison of F(ab ’ ) 2 to Fab 
for restoration of blood coagulability after  Daboia russellii 
in Sri Lanka. 24 
 We found no tradeoffs in safety related to immune reac-
tions or miscellaneous AEs. The plasma source for Fab is 
ovine, whereas for F(ab ’ ) 2 it is equine. It has been postu-
lated that immunizing sheep rather than horses could reduce 
risk associated with exposure to equine-produced allergenic 
components, 36 but immune reactions in all groups were low 
in this study, without discernible differences between the 
two antivenoms. Safety as it relates to coagulopathy, how-
ever, was better with F(ab ’ ) 2, consistent with results from 
Phase 2. 18 
 Limitations 
 Limitations of the study arose from the inclusion of a dis-
proportionate number of children in the F(ab ’ ) 2 /F(ab ’ ) 2 
group compared with that in the Fab/Fab group. None of the 
17 children treated with F(ab ’ ) 2 experienced late coagul-
opathy; however, late coagulopathies, some with medically 
signifi cant late bleeding, have been reported in children less 
than 10 years old, suggesting that the confounding effect 
of this group should be minimal. 26,37 This study was not 
powered to demonstrate the interaction of different snake 
venoms or site-specifi c populations with the primary 
endpoint, but the difference in geographic distribution of 
coagulopathic cases suggests that future studies should con-
sider the effects of heterologous antivenom(s) on many US 
Crotalinae species . 
 Conclusions 
 For envenomation by North American Crotalinae snakes 
capable of causing unexpected bleeding, this study found 
that management with longer-half-life F(ab ’ ) 2 antivenom 
reduces the risk of post-treatment recurrence and late-onset 
coagulopathies following treatment when compared with 
management with Fab. Until such time as F(ab ’ ) 2 is com-
mercially utilized in the US, patients with Crotalinae enven-
omation will be at continued risk for medically signifi cant 
late bleeding complications (including death) in the days and 
weeks following treatment with Fab. 
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